Renal cell carcinoma: Current prognostic factors

Cancer

Volumn 80, Issue 5, 1997, Pages 981-986

  Gelb, Arnold B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Grading; Outcome; Prognostic factors; Renal cell carcinoma; Staging

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; DNA; FERRITIN;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; DNA CONTENT; FERRITIN BLOOD LEVEL; HUMAN; HYPERCALCEMIA; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; WEIGHT REDUCTION;

ANEUPLOIDY; CARCINOMA, RENAL CELL; CELL NUCLEUS; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HEALTH STATUS INDICATORS; HUMANS; KIDNEY NEOPLASMS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030791061     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970901)80:5<981::AID-CNCR23>3.0.CO;2-R     Document Type: Article

References (70)

1. Burke HB, Henson DE. The American Joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system. Cancer 1993;72:3131-5.
2. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:979-85.
3. Montie JE. Current prognostic factors for prostate carcinoma. Cancer 1996;78:341-4.
4. Fielding LP, Henson DE. Multiple prognostic factors and outcome analysis in patients with cancer. Communication from the American Joint Committee on Cancer. Cancer 1993;71:2426-9.
5. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-35.
6. ASCO Tumor Marker Expert Panel. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.
7. Cancer facts & figures-1996. Atlanta: American Cancer Society, 1996.
8. Störkel S, Eble J, Adlakha K, Amin M, Blute M, Bostwick DG, et al. Classification of renal cell carcinoma. Cancer 1997; 80:985-7.
9. Grignon DJ, Hammond EH. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. Arch Pathol Lab Med 1995;119:1122-6.
10. Henson DE, Fielding LP, Grignon DJ, Page DL, Hammond ME, Nash G, et al. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee. Arch Pathol Lab Med 1995;119:1109-12.
11. Srigley JR, Hutter RV, Gelb AB, Henson DE, Kenney G, King B, et al. Current prognostic factors-renal cell carcinoma. Cancer 1997;80:992-4.
12. Gold PJ, Fefer A, Thompson JA. Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol 1996;14:216-22.
13. Ozen H, Uygur C, Sahin A, Tekgul S, Ergen A, Remzi D. Clinical significance of serum ferritin in patients with renal cell carcinoma. Urology 1995;46:494-8.
14. Thrasher JB, Paulson DF. Prognostic factors in renal cancer. Urol Clin North Am 1993;20:247-62.
15. Lanigan D. Prognostic factors in renal cell carcinoma. Br J Urol 1995;75:565-71.
16. Gospodarowicz MK, Monte JE. Renal cell carcinoma. In: Hermanek P, Gospodarowicz MK, Henson DE, Hutter RVP, Sobin LH, editors. Prognostic factors in cancer. New York: Springer-Verlag, 1995:234-40.
17. Kovacs G. The value of molecular genetic analysis in the diagnosis and prognosis of renal cell tumours. World J Urol 1994;12:64-8.
18. Wilhelm M, Krause U, Kovacs G. Diagnosis and prognosis of renal-cell tumors: a molecular approach. World J Urol 1995;13:143-8.
19. Shimazui T, Oosterwijk E, Debruyne FM, Schalken JA. Molecular prognostic factors in renal cell carcinoma. Semin Urol Oncol 1996;14:250-5.
20. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297-301.
21. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971;28:1165-77.
22. Medeiros LJ, Gelb AB, Weiss LM. Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer 1988;61:1639-51.
23. Giberti C, Oneto F, Martorana G, Rovida S, Carmignani G. Radical nephrectomy for renal cell carcinoma: long-term results and prognostic factors on a series of 328 cases. Eur Urol 1997;31:40-8.
24. Flocks RH, Kadesky MC. Malignant neoplasms of the kidney: an analysis of 353 patients followed 5 years or more. J Urol 1958;79:196-201.
25. Hermanek P, Schrott KM. Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma [see discussion]. J Urol 1990;144:238-41. Discussion in J Urol 1990;144:41-2.
26. Hermanek P, Schrott KM. Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma [see discussion]. J Urol 1990;144:238-41. Discussion in J Urol 1990;144:41-2.
27. Gelb AB, Shibuya RB, Weiss LM, Medeiros LJ. Stage I renal cell carcinoma. A clinicopathologic study of 82 cases. Am J Surg Pathol 1993;17:275-86.
28. Weiss LM, Gelb AB, Medeiros LJ. Adult renal epithelial neoplasms. Am J Clin Pathol 1995;103:624-35.
29. Robson CJ. Results of radical thoraco-abdominal nephrectomy in the treatment of renal cell carcinoma. Prog Clin Biol Res 1982;100:481-8.
30. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. American Joint Committee on Cancer. Manual for staging of cancer. 4th edition. Philadelphia: J. B. Lippincott, 1992:201-4.
31. Hermanek P, Sobin LH, editors. UICC TNM classification of malignant tumours. 4th edition. 2nd revision. New York: Springer-Verlag, 1992:148-50.
32. Association of Directors of Anatomical and Surgical Pathology. Recommendations for the reporting of resected neoplasms of the kidney. Hum Pathol 1996;20:1005-7.
33. Störkel S, Thoenes W, Jacobi GH, Lippold R. Prognostic parameters in renal cell carcinoma-a new approach. Eur Urol 1989;16:416-22.
34. Guinan P, Sobin L, Algaba F, Badellino F, Kameyama S, MacLennan G, et al. TNM staging of renal cell carcinoma. Cancer 1997;80:990-1.
35. Licht M, Novick A, Goormastic M. Nephron sparing surgery in incidental vs. suspected renal cell carcinoma. J Urol 1994;152:39-43.
36. 34a. Gelb AB, Sudilovsky D, Wu CD, Weiss LM, Medeiros LJ. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in locally confined renal cell carcinoma. Cancer (In press).
37. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
38. Green LK, Ayala AG, Ro JY, Swanson DA, Grignon DJ, Giacco GG, et al. Role of nuclear grading in stage I renal cell carcinoma. Urology 1989;34:310-5.
39. Hofmockel G, Tsatalpas P, Muller H, Dammrich J, Foot M, Mayer-Schultze B, et al. Significance of conventional and new prognostic factors for locally confined renal cell carcinoma. Cancer 1995;76:296-306.
40. Medeiros LJ, Jones EC, Aizawa S, Aldape H, Cheville JC, Goldstein N, et al. Grading of renal cell carcinoma. Cancer 1997;80:988-9.
41. Mancilla-Jimenez R, Stanley RJ, Blath RA. Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. Cancer 1976;38:2469-80.
42. Boczko S, Fromowitz FB, Bard RH. Papillary adenocarcnoma of the kidney: a new perspective. Urology 1979;14:491-5.
43. Mydlo JH, Bard RH. Anaysis of papillary renal adenocarcinoma. Urology 1987;30:529-34.
44. Varkarakis MJ, Bhanalaph T, Moore RH, Murphy GP. Prognostic criteria of renal cell carcinoma. J Surg Oncol 1974;6:97-107.
45. Thoenes W, Störkel S, Rumpelt HJ, Moll R, Baum HP, Werner S. Chromophobe cell renal carcinoma and its variants-a report on 32 cases. J Pathol 1988;155:277-87.
46. Akhtar M, Kardar H, Linjawi T, McClintock J, Ali MA. Chromophobe cell carcinoma of the kidney. A clinicopathologic study of 21 cases. Am J Surg Pathol 1995;19:1245-56.
47. Hamed G, Perez-Odonez B, Russo R, Gaudin PB, Reuter VE. Chromophobe renal cell carcinoma: a clinicopathologic study of 51 cases. Mod Pathol 1996;9:74A.
48. Crotty TB, Farrow GM, Lieber MM. Chromophobe cell renal carcinoma: clinicopathological features of 50 cases. J Urol 1995;154:964-7.
49. Goldstein NS, Bostwick DG. Histologic type and grade of renal cell carcinoma: clinical significance in 813 cases. Mod Pathol 1997;10:76A.
50. Kennedy SM, Merino MJ, Linehan WM, Roberts JR, Robertson CN, Neumann RD. Collecting duct carcinoma of the kidney. Hum Pathol 1990;21:449-56.
51. Tomera KM, Farrow GM, Lieber MM. Sarcomatoid renal carcinoma. J Urol 1983;130:657-9.
52. Ro JY, Ayala AG, Sella A, Samuels ML, Swanson DA. Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases. Cancer 1987;59:516-26.
53. Baer SC, Ro JY, Ordonez NG, Maiese RL, Loose JH, Grignon DJ, et al. Sarcomatoid collecting duct carcinoma: a clinicopathologic and immunohistochemical study of five cases. Hum Pathol 1993;24:1017-22.
54. Delahunt B, Becker RL, Bethwaite PB, Ribas JL. Computerized nuclear morphometry and survival in renal cell carcinoma: comparison with other prognostic indicators. Pathology 1994;26:353-8.
55. Shankey TV. Urological cancers. In: Bauer KD, Duque RE, Shankey TV, editors. Clinical flow cytometry: principles and application. Baltimore: Williams & Wilkins, 1993:271-301.
56. Flint A, Grossman HB, Liebert M, Lloyd RV, Bromberg J. DNA and PCNA content of renal cell carcinoma and prognosis. Am J Clin Pathol 1995;103:14-9.
57. Rainwater LM, Hosaka Y, Farrow GM, Lieber MM. Well differentiated clear cell renal carcinoma: significance of nuclear deoxyribonucleic acid patterns studied by flow cytom-etry. J Urol 1987;137:15-20.
58. Eskelinen M, Lipponen P, Nordling S. Prognostic evaluation of DNA flow cytometry and histo-morphological criteria in renal cell carcinoma. Anticancer Res 1995;15:2279-83.
59. Delahunt B, Ribas JL, Nacey JN, Bethwaite PB. Nucleolar organizer regions and prognosis in renal cell carcinoma. J Pathol 1991;163:31-7.
60. Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Kuhn R, Wittekind CW. Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer 1996;77:164-71.
61. Jochum W, Schroder S, al-Taha R, August C, Gross AJ, Berger J, et al. Prognostic significance of nuclear DNA content and proliferative activity in renal cell carcinomas. A clinicopathologic study of 58 patients using mitotic count, MIB-1 staining, and DNA cytophotometry. Cancer 1996;77:514-21.
62. de Riese WT, Crabtree WN, Allhoff EP, Werner M, Liedke S, Lenis G, et al. Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma. J Clin Oncol 1993;11:1804-8.
63. Bot FJ, Godschalk JC, Krishnadath KK, van der Kwast TH, Bosman FT. Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinicopathological parameters. Int J Cancer 1994;57:634-7.
64. Imai Y, Strohmeyer TG, Fleischhacker M, Slamon DJ, Koeffler HP. p53 mutations and Mdm-2 amplification in renal cell cancers. Mod Pathol 1994;7:766-70.
65. Shalitin C, Epelbaum R, Moskovitz B, Segal R, Valansi C, Werner M, et al. Increased levels of a 21-kDa protein in the circulation of tumor-bearing patients. Cancer Detect Prev 1994;18:357-65.
66. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EW, Moore DH, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
67. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87:1603-12.
68. Yoshimo S, Kato M, Okada K. Prognostic significance of microvessel count in low stage renal cell carcinoma. Int J Urol 1995;2:156-60.
69. MacLennan GT, Bostwick DG. Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology 1995;46:27-30.
70. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604-8.